Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
about
Glucocerebrosidase is shaking up the synucleinopathiesGlucocerebrosidase and Parkinson disease: Recent advancesConverging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseThe relationship between glucocerebrosidase mutations and Parkinson diseaseAmbroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cellsIdentification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry DiseaseDrug repositioning for enzyme modulator based on human metabolite-likeness.Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's diseaseDevelopment of targeted therapies for Parkinson's disease and related synucleinopathiesPharmacological chaperone therapy for lysosomal storage diseases.Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease.Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases.[More than expectorant: new scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases].Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease.Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Disease models for the development of therapies for lysosomal storage diseases.Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids.Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.New Directions in Gaucher Disease.Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.Gaucher disease: Progress and ongoing challenges.Small molecules as therapeutic agents for inborn errors of metabolism.Stabilization of Glucocerebrosidase by Active Site Occupancy.Drug repositioning can accelerate discovery of pharmacological chaperones.Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations.Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry.Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.The contribution of mutant GBA to the development of Parkinson disease in Drosophila.Neuraminidase 1 activates insulin receptor and reverses insulin resistance in obese mice.Modeling Parkinson's Disease in Drosophila: What Have We Learned for Dominant Traits?Gaucher diseaseEmerging Treatment Approaches for Parkinson's Disease
P2860
Q24337392-E6916042-D3B4-47AE-9682-4112B49E05D5Q27005669-82020C74-7EB7-439D-99DB-4993C524226FQ28074143-A3227008-5A0D-47C9-B746-6F84BD5DAB33Q28077257-240D37AB-23B5-4B8C-A266-57A7828AE8ADQ28308084-354AD6FD-6976-4F1C-BB01-23A63F430F83Q28553021-44C6448D-CFB8-4B8F-AFC1-95623F542C4FQ33802239-7CA37DA0-8951-4830-82FA-077BD20435D2Q34066863-09F0A6E4-2912-40F2-AEDD-CB45BC63730BQ34185956-BFA4691B-8E6B-4209-AC71-708BAB540A7FQ34238616-5D81B165-976B-4DAD-BFB9-EF107E3A69CAQ35214286-FC74F00F-369C-4A4D-9D1C-DCD9D31EE066Q35686212-1719189D-744C-477C-B68D-925B0499D24AQ35822086-2BEF6203-D1B7-423F-AF3C-F25D0E8C345FQ36217769-ED2F0A65-3C38-445B-A8EC-94D76A677DF2Q36413065-DCFC7963-0D8B-4E31-BC88-45983A10D5FFQ36653826-A833A982-75CC-43D2-AB28-3D4CEA36E53BQ37462136-FB4C2D34-1D67-43EF-B287-81471511A51AQ37619231-71396F23-57ED-4311-97F5-D00D46F6F2C2Q37738863-D819B476-1EDC-43D6-9F95-5E089689F7B6Q38161987-1FC6CCD6-A041-41AC-B82A-FEA2E38676FAQ38275171-4D4981DD-00BB-412E-B2FB-150B41573C5DQ38424066-F1A01AAC-01C9-4972-965B-06C6CB3194DFQ38648684-C29EA449-8545-4331-A304-F931978A8F39Q38727638-E33AC5B6-7FB5-4BD1-A83F-57AF64B7745DQ38905996-87A35A77-4690-4C14-B9F8-1E22BD1F320FQ38927256-CA9B9E14-4CCC-45F2-AA85-3D904F5B62CEQ39028972-C691C0D4-828D-44BD-98BF-03E5A9C5E53BQ39038060-D6AE0651-4347-4925-9CEC-625A0F205D63Q41110570-92074F70-7871-47D7-AB04-F608ADBD1B32Q42558415-8F5FF040-0627-42C7-B8AB-44E06E75F1D6Q50419934-F7C5E219-BA34-41BF-A927-BEF13D7AB8F0Q50858691-6DEC9D1A-9D7C-49AE-AE3E-832EE5336877Q52149452-FCE06EB4-C565-4993-B3E8-D4F200F9275FQ52848620-99A68B7B-2860-41A2-ABD8-B9F833F95A81Q53819711-7E5DF334-B548-482B-AEAC-BB04BE9D0B4AQ54114687-15A125A7-05C4-4DD8-A0D6-9AFCDC33C021Q56338451-658CCC36-4B79-4466-8596-233FAD77727FQ57817579-5659590F-91DA-4D6D-B8B5-CEECD1D06B10
P2860
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@en
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@nl
type
label
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@en
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@nl
prefLabel
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@en
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@nl
P2093
P2860
P1476
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
@en
P2093
Inna Bendikov-Bar
Mia Horowitz
Mirella Filocamo
P2860
P304
P356
10.1016/J.BCMD.2012.10.007
P577
2012-11-14T00:00:00Z